Cannabis News
What is AEF-0117?- Big Pharma’s New Drug to Get You Off of Cannabis and Back on Prescription Drugs As Soon As Possible
Can’t quit weed? Pharma says try this Experimental drug!
Are you tired of enjoying yourself and feeling relaxed? Do you find it too easy to laugh and forget about your worries? Are you convinced that you’re addicted and need a quick fix to outsource your problems to pot? Well, fret no more! We have the perfect solution just for you: “Weed-B-Gone™”!
“Weed-B-Gone™” is the groundbreaking pharmaceutical wonder that targets your CB1 receptors, putting an end to all that pesky enjoyment and relaxation caused by cannabis use. Say goodbye to those moments of creativity and introspection! With “Weed-B-Gone™,” you’ll be back to your mundane and monotonous routine in no time.
But wait, there’s more! “Weed-B-Gone™” offers an array of delightful side effects, including dry mouth, nausea, anxiety, and a general sense of dissatisfaction. Say goodbye to those pesky giggles and warm fuzzy feelings, and hello to a whole new world of discomfort!
So why waste another moment feeling good when you can join the ranks of the perpetually grumpy and uninspired? Try “Weed-B-Gone™” today and rediscover the joys of a mundane existence. Remember, life is better when you’re not having fun!
Some of you might be laughing – but pharma is working on this right now!
In a recent article in the NY Post, there was an article about a “promising new drug” called AEF-0117, which allegedly can help combat “marijuana addiction”.
In a bid to capitalize on the increasing prevalence of cannabis consumption in the US, pharmaceutical companies have introduced a new pill that claims to combat marijuana addiction. The experimental drug, AEF-0117, has shown promise in a small trial by reducing the addictive impact of THC, the primary psychoactive compound in cannabis. While the study published in the journal Nature Medicine may appear encouraging at first glance, a closer examination raises several concerns about the motives behind such pharmaceutical interventions.
In this article, I’m only going to focus in on their questionable claims, if you want to read about the drug itself, I recommend clicking the link above.
Questionable Claims and Lack of FDA Approval:
The article highlights the positive results of the study, emphasizing the reduction of cannabis’s “good effects” by up to 38% among participants who took the higher dose of AEF-0117. However, it’s important to note that there is currently no FDA-approved medication available to treat cannabis-use disorder. The reason there is no FDA approved medication is because we’re talking about the endocannabinoid system. Previous drugs have made people vomit and get severely ill, because the ECS is a major system that maintains homeostasis in the body.
Therefore, if you’re simply going to be blocking CB1 receptors, and something goes wrong – it could be the difference between being healthy and your body deciding to kill you because it thinks you’re a virus. The ECS is responsible for maintaining your systems and when you’re messing with that – you could be messing with many things.
This is why in the past, no drug has been approved and why this one seems “promising” because it hasn’t had any of those side effects.
Limited Sample Size.
The trial involved only 29 individuals diagnosed with cannabis-use disorder who consumed an average of 3 grams of cannabis six days a week. While the results may be significant within this limited sample, extrapolating them to the broader population of cannabis users requires caution.
Of course, this is only the first of the trials and they will be scaling it up in order to work out these kinks – but this leads to one thing, motivation.
Why are they targeting the “feel good” effects of cannabis and why aren’t they doing that with alcohol. If this is a pharmacological strategy, why is it with cannabis and not alcohol that this type of treatments are being developed?
Targeting “Good Effects” and Unanswered Questions:
The focus of the drug seems to be on reducing the perceived “good effects” of cannabis. However, it is important to consider the reasons why individuals consume cannabis, which may include stress relief, relaxation, and enjoyment.
The article fails to address whether reducing these effects aligns with the goals and preferences of individuals seeking help for cannabis use. Furthermore, the potential long-term consequences and unintended effects of suppressing these natural experiences remain unknown as mentioned above.
Furthermore, as an “ex-addict” to tobacco, which is statistically as addictive as heroin…you don’t need to “take away the feel good” elements of a substance to reduce the importance of a substance in the minds of the addict.
It’s a process of deprogramming, of healing parts of the self – a single pill won’t let their underlying problems go away. It will simply steal them of their ability to use cannabis as a mechanism of relief.
Overemphasis on Cannabis Addiction:
While the article highlights the prevalence of cannabis addiction among younger consumers, it is crucial to acknowledge that the majority of cannabis users do not develop problematic patterns of use. The sensationalized narrative surrounding cannabis addiction risks stigmatizing responsible users and overshadowing the plant’s potential benefits in various therapeutic contexts.
They claim that 9% of the cannabis population suffers from CUD, however, this is a population that suffers from other things. Cannabis is simply the chosen substance they use to escape their problems. 9 out of 10 times, they are poor, from broken homes, parents fed them ADHD medication since they were five – yet Cannabis is the problem!
Pharmaceutical attempts to “cure” weed addiction with drugs like AEF-0117 raise concerns about their underlying motivations and the potential risks of medicalizing normal human experiences.
As the larger trial is yet to be conducted, it is essential to critically evaluate the claims made in this small study and to prioritize a comprehensive understanding of cannabis use and its potential effects.
Instead of seeking quick-fix solutions, a nuanced approach involving education, harm reduction strategies, and evidence-based treatment options would better serve individuals seeking help for cannabis use-related issues.
Addiction is not as difficult as people think. It’s simply messy, and in most cases – the “physical addiction” is the easier thing to fix.
Addiction is a snake that entangles itself into your belief systems. You then take the addiction and substance, and make it a fundamental part of your identity. You believe it provides you relief to the symptoms of your problems, however, upon further investigation you’ll see that it causes those problems.
To those who read this and say, “I suffer from cannabis addiction”, I’m not denying your experience either.
There are people who suffer from addiction, but no pill will undo the entanglement. First, you must have a true desire to quit and recognize your underlying issues – and then, you have to systematically face every “belief” you have around that addiction and challenge them.
Replace them, and automatically you’ll quit.
It’s not easy, it’s peering into your internal darkness. It hurts, but it’s definitely possible! You just have to become someone else…and allow the old addict to die.
But Pharma’s quick fix to me seems Sketchy AF.
More about AEF-0117 here – https://clinicaltrials.gov/ct2/show/NCT03717272
ADDICTED TO CANNABIS? READ ON…
